Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exclusive License and Distribution Agreement

23 Nov 2009 07:00

RNS Number : 8872C
Plethora Solutions Holdings PLC
23 November 2009
 



23rd November 2009

PLETHORA SOLUTIONS AND COLUMBIA LABORATORIES EXECUTE EXCLUSIVE MARKETING AGREEMENT FOR STRIANT SR®

London, UK and Livingston, NJ - November 23, 2009 - Plethora Solutions Holdings PLC ("Plethora", AIM: PLE) and Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that they have executed an exclusive license and distribution agreement whereby Plethora will market Columbia's Striant SR® 30 mg mucoadhesive buccal tablets for testosterone replacement therapy in men with hypogonadism in the UK. The product received UK marketing approval from the Medicines and Healthcare Regulatory Authority in 2004. 

Declining testosterone levels ("late onset" hypogonadism) are a natural consequence of aging. Epidemiological studies suggest that over one third of men aged 45 years or more visiting primary care practices have low testosterone levels and of the eight million men aged between 45 and 65 living in the UK, it is estimated that over 2.5 million have lower than normal testosterone levels and might benefit from testosterone replacement therapy. In some men, low testosterone causes fatigue, lethargy, loss of libido and erectile dysfunction and in the longer term, a higher risk of osteoporosis and bone fracture. Low testosterone is more common in men with Type 2 diabetes and is associated with visceral obesity and insulin resistance. The importance of evaluating testosterone levels in symptomatic men and the use of testosterone replacement therapy is recognised by leading authorities including the International Society of Andrology and the European Association of Urology. 

Striant SR® is a unique formulation of native testosterone delivered in a small patch-like tablet which adheres to the buccal mucosa, the small, natural depression in the mouth where the gum meets the upper lip above the incisor teeth. As it is exposed to saliva, the product softens into a gel-like form, which remains comfortably in place over each 12-hour dosing period. Striant SR® releases testosterone into the blood stream and restores and maintains circulating testosterone at normal levels. The product will be marketed by Plethora's newly formed subsidiary, The Urology Company Limited.

Steven Powell, Chief Executive Officer of Plethora, commented"The benefits of testosterone replacement therapy are recognised by urologists and andrologists as an effective means of restoring full sexual function and increasingly as a means of better controlling obesity and other symptoms common in men with diabetes and other metabolic conditionsA number of testosterone products are available in the UK, such as gels and patches, but we believe thaStriant SR offers patients a convenient alternative." 

Columbia Laboratories' Chief Executive Officer Robert S. Mills stated, "Ware pleased that Striant SR® will be available to medical practitioners in the UK and that their male patients will benefit from its convenience and ability to rapidly restore normal levels of testosterone."

-Ends-

Enquiries:

Plethora Solutions

Steven Powell

Tel : +44(0) 20 3077 5400

Hansard Group

Adam Reynolds/John Bick

Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE) 

Further information is available at www.plethorasolutions.co.uk

About Columbia:

Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and marketing products for the reproductive healthcare and endocrinology markets using its novel bioadhesive drug delivery technology. Further information is available at www.columbialabs.com.

Columbia Laboratories, Inc.

Investor and Media Contact:

Lawrence A. Gyenes

Melody A. Carey, 

Senior Vice President, Chief Financial & Treasurer

Co-President, Rx Communications, LLC

(973) 486-8860

(917) 322-2571

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRCKKKPFBDDADB
Date   Source Headline
9th Mar 20168:15 amRNSScheme becomes Effective
8th Mar 20164:44 pmRNSCourt Sanction of Scheme - Replacement
8th Mar 20163:12 pmRNSScheme becomes Effective
8th Mar 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
8th Mar 20167:30 amRNSSuspension - Plethora Solutions Holdings Plc
7th Mar 20161:36 pmRNSSuspension of trading of Shares
7th Mar 20169:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
4th Mar 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
3rd Mar 20165:25 pmRNSR&D Tax Credit Receipt and Director Dealing
3rd Mar 201611:47 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
2nd Mar 201612:00 pmRNSResult of Shareholder and Court Meetings
2nd Mar 201611:20 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
1st Mar 201610:23 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
29th Feb 201611:14 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
26th Feb 20167:34 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
25th Feb 20169:33 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
24th Feb 20169:00 amRNSLetter of Intent Signed
24th Feb 20168:50 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
23rd Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
22nd Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
19th Feb 20167:50 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
18th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
17th Feb 201611:30 amRNSDisposal of Shares in Endeavour Mining Corporation
17th Feb 20168:29 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
16th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
15th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
12th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
11th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
11th Feb 20168:28 amRNSExpected timetable for suspension and de-listing
10th Feb 201611:35 amBUSForm 8.3 - Plethora Solutions Holdings Plc
10th Feb 20169:30 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
9th Feb 20163:24 pmRNSDirector/PDMR Shareholding
8th Feb 20168:11 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
5th Feb 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions Hldgs PLC
4th Feb 20169:00 amRNSPosting Scheme Document & Plethora Trading Update
3rd Feb 20169:29 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
2nd Feb 20162:52 pmRNSForm 8.3 - Plethora Solutions Holdings Plc
2nd Feb 20168:11 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
1st Feb 20168:34 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
29th Jan 20168:34 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
28th Jan 20169:06 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
27th Jan 20169:01 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
26th Jan 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
26th Jan 20169:00 amRNSTrading Update
25th Jan 20169:24 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
25th Jan 20169:00 amRNSOffer Update
22nd Jan 201611:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions Hldgs PLC
21st Jan 20169:02 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
20th Jan 20169:00 amRNSForm 8 (OPD) (Plethora Solutions) - Replacement
20th Jan 20168:30 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.